Press Releases

Archives: Search / 2017

2016201520142013201220112010200920082007

2016 Archives

Dec 19, 2016

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Eisai Laboratórios Ltda., a subsidiary of Eisai Inc., has received regulatory approval from the Brazilian Health...

More
Dec 12, 2016

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of two posters highlighting the latest data on elenbecestat (development code: E2609), its...

More
Dec 12, 2016

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced new interim data investigating Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in...

More
Dec 5, 2016
Presentations Include Analysis of Real-World Use and Post-Hoc Analysis of Long-Term Safety and Efficacy

Eisai Inc. announced today new analyses and data on perampanel presented at the 2016 Annual Meeting of the American Epilepsy Society (AES). Perampanel, marketed as FYCOMPA® CIII, is indicated as...

More
Dec 5, 2016

Eisai Inc. announced today final results of its Phase 3 open-label two-year study of rufinamide, which were presented at the 2016 Annual Meeting of the American Epilepsy Society (AES) held from...

More
Dec 1, 2016

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Rebecca Jolley as Senior Vice President Americas Commercial, Oncology Business...

More
Nov 30, 2016

Eisai Inc. announced today the presentation of new data from studies of eribulin, marketed under the brand name Halaven®, at the 2016 San Antonio Breast Cancer Symposium (SABCS). Two ongoing...

More
Nov 28, 2016

Eisai Inc. announced today the presentation of 12 posters during the 70th annual American Epilepsy Society (AES) Annual Meeting, highlighting data from the company's anti-epileptic drugs FYCOMPA®...

More
Nov 17, 2016

Eisai Inc. announced today that it has received U.S. Food and Drug Administration (FDA) Fast Track designation for the development of E2609, a Beta-secretase Cleaving Enzyme (BACE) inhibitor...

More
Nov 3, 2016

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the presentation of one oral presentation and one poster at Obesity Week(SM) regarding new data on BELVIQ® (lorcaserin...

More
Oct 31, 2016

Eisai Inc. and Purdue Pharma L.P. announced today the initiation of a multi-center, randomized Phase 2 clinical study (Study 202) to evaluate Eisai's internally-discovered oral dual orexin...

More
Oct 31, 2016

Eisai Inc. announced today that enrollment has begun in the U.S. for MISSIONAD, a Phase 3 clinical program for E2609, a Beta-secretase Cleaving Enzyme (BACE) inhibitor for patients with early...

More
Oct 28, 2016
Trials to assess perampanel in those with Lennox-Gastaut Syndrome, a rare form of epilepsy, and in children with partial-onset seizures now enrolling patients

Eisai Inc. announced today the initiation of two multi-center, global Phase 3 clinical trials assessing FYCOMPA® (perampanel) CIII in two different patient populations: patients age 2 years and...

More
Oct 26, 2016
Two other Eisai-marketed products -- HALAVEN® (eribulin mesylate) and BELVIQ® (lorcaserin HCI) CIV -- also collect nominations

Eisai Inc. announced today that LENVIMA® (lenvatinib), the company's multiple receptor tyrosine kinase inhibitor (TKI), has been nominated for Best Pharmaceutical Product at the 10th Annual Prix...

More
Oct 26, 2016
"Medikidz Explain LGS," endorsed by leading advocacy groups, educates public on rare and severe form of epilepsy

Eisai Inc. today announced the launch of "Medikidz Explain Lennox-Gastaut Syndrome (LGS)," an educational comic book designed to inform people about LGS, a rare type of epilepsy that is usually...

More
Oct 26, 2016

Eisai Inc. and the Oklahoma Medical Research Foundation (OMRF) have formed a research collaboration to study the autoimmune disease lupus. Under the new agreement, Eisai's research team at its...

More
Oct 13, 2016
Study Evaluated Maximum Tolerated Dose

Eisai Inc. announced today the presentation of preliminary results of a Phase 1b clinical study (Study 111) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib...

More
Oct 3, 2016
New FDA-Approved Formulation Offers Patients a Once-Daily Dosing Option for Chronic Weight Management

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the availability of BELVIQ XR® (lorcaserin HCl) CIV extended-release 20 mg tablets, a new once-daily dosing option that...

More
Sep 29, 2016

Eisai Inc. announced today the presentation of seven abstracts featuring data on its cancer treatments at the European Society of Medical Oncology (ESMO) 2016 Congress. The abstracts highlight new...

More
Sep 29, 2016
Eisai's CLEAR study will compare the company's multiple receptor TKI, lenvatinib, plus the anti-PD-1 pembrolizumab and lenvatinib plus the mTOR inhibitor everolimus versus sunitinib, the current standard of care in this setting

Eisai Inc. announced today the initiation of a multicenter, global, randomized Phase 3 study that will evaluate the efficacy and safety of two regimens containing Eisai's multiple receptor...

More
Sep 26, 2016
Application Based on New FDA Communication Supporting Use as Monotherapy for the Treatment of Partial Onset Seizures Based on Extrapolation

Eisai Inc. announced today that it has submitted a supplemental application to the U.S. Food and Drug Administration (FDA) for a proposed label change for its antiepileptic drug FYCOMPA®...

More
Sep 22, 2016
METAvivor and Eisai Inc. Partner to Urge MBC Community to Discuss Living with Their Diagnosis, How They Draw Strength and Encouragement from Their Support Networks

"The cancer has spread. We can offer you treatment, but ultimately, it is incurable." A metastatic breast cancer (MBC) diagnosis comes with many medical, practical and emotional challenges as...

More
Sep 21, 2016
The Light of Life Foundation, ThyCa: Thyroid Cancer Survivors' Association, and Eisai Team Up to Increase Awareness by Urging People with Thyroid Cancer to Share their Experiences

A thyroid cancer diagnosis can lead to significant distress as patients and caregivers cope with various medical, emotional and economic challenges, as survivors, patients and caregivers have...

More
Sep 21, 2016

Eisai Inc. announced today the presentation of abstracts at the 86th Annual Meeting of the American Thyroid Association (ATA) that highlight an investigational Phase 2 trial currently recruiting...

More
Sep 15, 2016
Discovery innovation unit of 90 scientists at dedicated research facility to use human genetics and related data to develop novel, targeted medicines for dementia and oncology

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has announced the launch of the Eisai Andover innovative Medicines (AiM) Institute, a discovery innovation unit within the...

More
 

print email rss